Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ajh.24479 http://scihub22266oqcxt.onion/10.1002/ajh.24479 C5129477!5129477 !27415835     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27415835 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Am+J+Hematol 2016 ; 91 (10 ): 1026-31 Nephropedia Template TP {{tp|p=27415835 |t=2016. Deferiprone-induced agranulocytosis: 20 years of clinical observations |pdf=|usr=}}{{27415835 }} gab.com Text Deferiprone-induced agranulocytosis: 20 years of clinical observations JO: Am J Hematol http://www.kidney.de/pget.php?&tw=1&pmid=27415835 #FOAvip Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC). Here, we analyze all episodes of agranulocytosis (n?=?161) and neutropenia (n?=?250) during deferiprone use in clinical trials (CT) and postmarketing surveillance programs (PMSP). Rates of agranulocytosis and neutropenia in CT were 1.5% and 5.5%, respectively. Of the agranulocytosis cases, 61% occurred during the first 6 months of therapy and 78% during the first year. These events appeared to be independent of dose, and occurred three times more often in females than males. Their duration was not significantly shortened by use of G-CSF. No patient with baseline neutropenia (n?=?12) developed agranulocytosis during treatment, which raises questions about the validity of prior neutropenia as a contraindication to use. Only 1/7 novel neutropenia cases in CT progressed to agranulocytosis with continued treatment, indicating that neutropenia does not necessarily lead to agranulocytosis. The agranulocytosis fatality rate was 0% in CT and 15/143 (11%) in PMSP. Rechallenge with deferiprone produced agranulocytosis in 75% of patients in whom the event had already occurred, and in 10% with previous neutropenia. Weekly ANC monitoring allows early detection and interruption of therapy, but does not prevent agranulocytosis from occurring. Its relevance appears to decrease after the first year of therapy, when agranulocytosis occurs less often. Based upon analysis of data collected over the past 20 years, it appears that patient education may be the key to minimizing agranulocytosis-associated risks during deferiprone therapy. Am. J. Hematol. 91:1026-1031, 2016. © 2016 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc. Twit Text FOAVip Deferiprone-induced agranulocytosis: 20 years of clinical observations ????Am J Hematol http://www.kidney.de/pget.php?&tw=1&pmid=27415835 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27415835 #FOAvip English Wikipedia <ref>{{Cite pmid|27415835 }}</ref> Deferiprone-induced agranulocytosis: 20 years of clinical observations #MMPMID27415835 Tricta F ; Uetrecht J ; Galanello R ; Connelly J ; Rozova A ; Spino M ; Palmblad J Am J Hematol 2016[Oct]; 91 (10 ): 1026-31 PMID27415835 show ga Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC). Here, we analyze all episodes of agranulocytosis (n?=?161) and neutropenia (n?=?250) during deferiprone use in clinical trials (CT) and postmarketing surveillance programs (PMSP). Rates of agranulocytosis and neutropenia in CT were 1.5% and 5.5%, respectively. Of the agranulocytosis cases, 61% occurred during the first 6 months of therapy and 78% during the first year. These events appeared to be independent of dose, and occurred three times more often in females than males. Their duration was not significantly shortened by use of G-CSF. No patient with baseline neutropenia (n?=?12) developed agranulocytosis during treatment, which raises questions about the validity of prior neutropenia as a contraindication to use. Only 1/7 novel neutropenia cases in CT progressed to agranulocytosis with continued treatment, indicating that neutropenia does not necessarily lead to agranulocytosis. The agranulocytosis fatality rate was 0% in CT and 15/143 (11%) in PMSP. Rechallenge with deferiprone produced agranulocytosis in 75% of patients in whom the event had already occurred, and in 10% with previous neutropenia. Weekly ANC monitoring allows early detection and interruption of therapy, but does not prevent agranulocytosis from occurring. Its relevance appears to decrease after the first year of therapy, when agranulocytosis occurs less often. Based upon analysis of data collected over the past 20 years, it appears that patient education may be the key to minimizing agranulocytosis-associated risks during deferiprone therapy. Am. J. Hematol. 91:1026-1031, 2016. © 2016 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc. |Adolescent [MESH] |Adult [MESH] |Aged [MESH] |Aged, 80 and over [MESH] |Agranulocytosis/*chemically induced [MESH] |Child [MESH] |Child, Preschool [MESH] |Clinical Trials as Topic/statistics & numerical data [MESH] |Deferiprone [MESH] |Female [MESH] |Humans [MESH] |Iron Chelating Agents/adverse effects/therapeutic use [MESH] |Iron Overload/drug therapy/etiology [MESH] |Leukocyte Count [MESH] |Male [MESH] |Middle Aged [MESH] |Neutropenia/chemically induced [MESH] |Neutrophils/cytology [MESH] |Patient Education as Topic [MESH] |Product Surveillance, Postmarketing/statistics & numerical data [MESH] |Pyridones/*adverse effects/therapeutic use [MESH] |Risk Factors [MESH] |Sex Factors [MESH] |Thalassemia/complications [MESH]Deferiprone-induced agranulocytosis: 20 years of clinical observations(epmc).pdf DeepDyve Pubget Overpricing